Sun Pharma's research arm Sun Pharma Advanced Research Company (SPARC) and China's biotech firm HitGen Wednesday announced a collaboration to identify novel small molecule leads for targets of interest.
Under the terms of the agreement, HitGen will receive upfront payment and will be eligible for certain milestone payments.
"Under this collaboration, HitGen will apply its advanced technology platform, based on DNA-encoded library design, synthesis and screening, to discover novel leads for SPARC," both companies said in a joint statement.
The statement, however, did not elaborate on details of the payments.
HitGen Chairman of the board and chief executive officer Jin Li said the company will work closely with SPARC scientists to generate novel leads for their innovative research programmes to address unmet medical needs.
HitGen is a biotech company with headquarters and main research facilities based in Chengdu, China, and a subsidiary in the USA.
Shares of SPARC were trading 2.08 per cent higher from its previous close at Rs 200.80 apiece on BSE.
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.